The Board

Introduction to the IML team, our Board of Directors and the experts and members of our various working groups with whom we collaborate.

The Board of Directors sets IML's strategic priorities, its key objectives and approves IML's policy positions, thus ensuring good governance and alignment of IML's public policies in a local context.



Aurélie Boob

Public Affairs Associate
Elisa Dolci

Elisa Dolci

European Engagement Project Manager


Task force and experts

Eline Darquennes

Evidence, data and Access Policy Lead, External Affairs Department - MSD - Merck Sharp & Dohme

Charline Desmecht

Corporate Affairs Lead - UCB

Robert Henkinet

External Relations Lead - Janssen-Cilag

Muriel L'Heureux

Patient Journey Partner Neurosciences - Roche

Birce Suntay

Senior Market Access Manager - BMS

Petra Faes

Senior Market Access Manager - Bayer

Sébastien Massart

Director Market Access, Pricing and Governmental Affairs - Merck

David Gaier

Governmental Affairs and Policy Manager - Bristol Myers Squibb

Christine Petit

Head of Public Affairs & Market Access

Laurence Pierard

Market Access Lead Immunology BeLux - Abbvie

Ingrid Vertongen

Corporate Communications Benelux - Bristol Myers Squibb

Davy T’Jampens

Head of Patient Value & Access - Takeda

Janice Geers

Senior manager Health Economics, Market Access & Reimbursement - Janssen-Cilag B.V

Shirley Lantreibecq

Market Access Manager - COO - AstraZeneca

Birce Suntay

Senior Market Access Manager - BMS

Liesbet Herteleer

Access Value Manager - Roche

Marilyn Coppenrath

Head Market Access & Public Affairs - Boehringer Ingelheim
Become a member

Interested in becoming a partner?

To benefit from all of our services, more particularly :

  • Participate in committees and commissions, in the different working groups
  • Free access to our intranet
  • Profit of the organizations networh:  exchangres between experts, invitation to formations and exclusive meetings (economical, scientific, industrial, social, legal, RSE, parlementary, european, communication…)
  • Being represented and being defended in front of institutions and the public, see the image of drug producing companies valued.

for more detailed information about the adhesion steps, please, contact us by mail .